Skip to main content

Vivos Therapeutics, Inc.

VVOS
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001716166

No open-market purchases or sales by Vivos Therapeutics, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $242.7K in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Vivos Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Vivos Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Vivos Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Sokolow Leonard JDirector–Sep 18, 20261
Johnson Gregg CDirector–Sep 18, 20261
Huntsman Ronald KirkChief Executive Officer85,910IndirectSep 18, 20261
Amman Bradford K.Principal Accounting Officer250,080Aug 26, 20261
Skaff Michael C10% Owner1,353,625IndirectJul 15, 20262
V-Co Investors 3 LLC10% Owner1,353,625IndirectApr 2, 20261
Krammer Anja BDirector–Jun 28, 20240
Thompson MatthewDirector–Jun 28, 20240
Lindsay Mark F.Director–Jun 28, 20240
Green Ralph EliasDirector–Jun 28, 20240
Singh Gurdev DaveChief Medical Officer–Aug 10, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 15, 2026 (view filing)4:23 PM ETJun 3015 daysLateSkaff Michael C10% OwnerPPurchase+5.50M$0.582+$3.20M–2.75M afterDerivative3 lots
Apr 2, 2026 (view filing)7:34 PM ETMar 312 daysSkaff Michael C and 1 other10% OwnerPPurchase+1.35M$1.34+$1.81MNew position1.35M after2 lots
Apr 2, 2026 (view filing)7:34 PM ETMar 312 daysSkaff Michael C and 1 other10% OwnerPPurchase+4.00M$1.34+$5.36M–1.78M afterDerivative3 lots
Jun 20, 2023 (view filing)Jun 20Same dayHuntsman Ronald KirkChief Executive OfficerPPurchase+14.0K$0.53+$7.42K+19.3%86.5K after
Jun 20, 2023 (view filing)Jun 15-165 daysHuntsman Ronald KirkChief Executive OfficerPPurchase+15.0K$0.5366+$8.06K+26.1%72.5K after3 lots
Jun 15, 2023 (view filing)7:15 PM ETJun 141 dayHuntsman Ronald KirkChief Executive OfficerPPurchase+10.0K$0.49+$4.90K+21.1%57.5K after
Dec 28, 2022 (view filing)9:45 PM ETDec 235 daysHuntsman Ronald KirkChief Executive OfficerPPurchase+20.0K$0.50+$10.0K+72.7%47.5K after
Jun 3, 2022 (view filing)May 31-Jun 13 daysLateHuntsman Ronald KirkChief Executive OfficerPPurchase+12.0K$1.96+$23.6K+77.4%27.5K after2 lots
Sep 22, 2021 (view filing)Sep 211 dayHuntsman Ronald KirkChief Executive OfficerPPurchase+5.00K$4.31+$21.6K+47.6%15.5K after
Aug 18, 2021 (view filing)Aug 171 dayHuntsman Ronald KirkChief Executive OfficerPPurchase+5.00K$3.00+$15.0K+90.9%10.5K after